Phase 2 Trial of AZD1775 for Squamous Cell Lung Cancer
AZD1775 is an inhibitor of the Wee1 kinase, which is linked to chemotherapy resistance.
Title: A Phase II Trial of AZD1775 Plus Carboplatin-Paclitaxel in Squamous Cell Lung Cancer1
Principal Investigators: Jhanelle Gray, MD, H. Lee Moffitt Cancer Center and Research Institute
Description: For this single-group assignment phase 2 trial (ClinicalTrials.gov Identifier: NCT02513563), researchers are evaluating the safety and efficacy of AZD1775 with carboplatin and paclitaxel among patients with squamous cell lung cancer. AZD1775 is an inhibitor of the Wee1 kinase, which is linked to chemotherapy resistance.
All patients will receive 5 doses of combination carboplatin, paclitaxel, and AZD1775 over a 21-day cycle; treatment will be twice daily on days 1 and 2 and once on day 3.
Included patients will have advanced or metastatic disease without curative options. Prior chemotherapy, radiotherapy, checkpoint inhibition, or vaccine therapy is allowed.
For more study information, including inclusion and exclusion criteria, study locations, and contact information, visit https://clinicaltrials.gov/ct2/show/NCT02513563.
Status: This study is open and recruiting patients as of February 22, 2018.
This study is sponsored by the H. Lee Moffitt Cancer Center and Research Institute.
- Clinicaltrials.gov. AZD1775 plus carboplatin-paclitaxel in squamous cell lung cancer. NCT02513563. https://clinicaltrials.gov/ct2/show/NCT02513563. Accessed February 22, 2018.